Skip to main content
main-content

01.12.2012 | Primary research | Ausgabe 1/2012 Open Access

Cancer Cell International 1/2012

Down-regulation of cellular FLICE-inhibitory protein (Long Form) contributes to apoptosis induced by Hsp90 inhibition in human lung cancer cells

Zeitschrift:
Cancer Cell International > Ausgabe 1/2012
Autoren:
Qilin Wang, Wendong Sun, Xuexi Hao, Tianliang Li, Ling Su, Xiangguo Liu
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1475-2867-12-54) contains supplementary material, which is available to authorized users.
Qilin Wang, Wendong Sun contributed equally to this work.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

XGL and LS conducted the project design. QLW, WDS, XXH, TLL and LS conducted the experiments and data analysis. QL W and XG L drafted the manuscript. XG L managed the funding acquisition, supervised the project and was involved in interpretation of data and revision of the manuscript. All authors have contributed and approved the final manuscript.

Abstract

Background

Cellular FLICE-Inhibitory Protein (long form, c-FLIPL) is a critical negative regulator of death receptor-mediated apoptosis. Overexpression of c-FLIPL has been reported in many cancer cell lines and is associated with chemoresistance. In contrast, down-regulation of c-FLIP may drive cancer cells into cellular apoptosis. This study aims to demonstrate that inhibition of the heat shock protein 90 (Hsp90) either by inhibitors geldanamycin/17-N-Allylamino-17-demethoxygeldanamycin (GA/17-AAG) or siRNA technique in human lung cancer cells induces c-FLIPL degradation and cellular apoptosis through C-terminus of Hsp70-interacting protein (CHIP)-mediated mechanisms.

Methods

Calu-1 and H157 cell lines (including H157-c-FLIPL overexpressing c-FLIPL and control cell H157-lacZ) were treated with 17-AAG and the cell lysates were prepared to detect the given proteins by Western Blot and the cell survival was assayed by SRB assay. CHIP and Hsp90 α/β proteins were knocked down by siRNA technique. CHIP and c-FLIPL plasmids were transfected into cells and immunoprecipitation experiments were performed to testify the interactions between c-FLIPL, CHIP and Hsp90.

Results

c-FLIPL down-regulation induced by 17-AAG can be reversed with the proteasome inhibitor MG132, which suggested that c-FLIPL degradation is mediated by a ubiquitin-proteasome system. Inhibition of Hsp90α/β reduced c-FLIPL level, whereas knocking down CHIP expression with siRNA technique inhibited c-FLIPL degradation. Furthermore, c-FLIPL and CHIP were co-precipitated in the IP complexes. In addition, overexpression of c-FLIPL can rescue cancer cells from apoptosis. When 17-AAG was combined with an anti-cancer agent celecoxib(CCB), c-FLIPL level declined further and there was a higher degree of caspase activation.

Conclusion

We have elucidated c-FLIPL degradation contributes to apoptosis induced by Hsp90 inhibition, suggesting c-FLIP and Hsp90 may be the promising combined targets in human lung cancer treatment.
Zusatzmaterial
Authors’ original file for figure 1
12935_2012_375_MOESM1_ESM.tiff
Authors’ original file for figure 2
12935_2012_375_MOESM2_ESM.tiff
Authors’ original file for figure 3
12935_2012_375_MOESM3_ESM.tiff
Authors’ original file for figure 4
12935_2012_375_MOESM4_ESM.tiff
Authors’ original file for figure 5
12935_2012_375_MOESM5_ESM.tiff
Authors’ original file for figure 6
12935_2012_375_MOESM6_ESM.tiff
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2012

Cancer Cell International 1/2012 Zur Ausgabe